Peter Sander

List of Publications by Year
in descending order

90 papers	4,948 citations	87888 38 h-index	98798 67 g-index
94 all docs	94 docs citations	94 times ranked	5423 citing authors

#	Article	IF	Citations
1	Mycobacterium tuberculosis Prevents Inflammasome Activation. Cell Host and Microbe, 2008, 3, 224-232.	11.0	345
2	Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRÎ² repertoire. Nature Communications, 2014, 5, 3866.	12.8	267
3	A Single 16S Ribosomal RNA Substitution Is Responsible for Resistance to Amikacin and Other 2â€Deoxystreptamine Aminoglycosides in<i>Mycobacterium abscessus</i>and<i>Mycobacterium chelonae</i>. Journal of Infectious Diseases, 1998, 177, 1573-1581.	4.0	210
4	Fitness Cost of Chromosomal Drug Resistance-Conferring Mutations. Antimicrobial Agents and Chemotherapy, 2002, 46, 1204-1211.	3.2	205
5	Mechanisms of Streptomycin Resistance: Selection of Mutations in the 16S rRNA Gene Conferring Resistance. Antimicrobial Agents and Chemotherapy, 2001, 45, 2877-2884.	3.2	156
6	The Role of Antibiotic-Target-Modifying and Antibiotic-Modifying Enzymes in Mycobacterium abscessus Drug Resistance. Frontiers in Microbiology, 2018, 9, 2179.	3.5	155
7	A synthetic mammalian gene circuit reveals antituberculosis compounds. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9994-9998.	7.1	153
8	rpsL+: a dominant selectable marker for gene replacement in mycobacteria. Molecular Microbiology, 1995, 16, 991-1000.	2.5	152
9	The majority of inducible DNA repair genes in Mycobacterium tuberculosis are induced independently of RecA. Molecular Microbiology, 2003, 50, 1031-1042.	2.5	141
10	Structural basis for selectivity and toxicity of ribosomal antibiotics. EMBO Reports, 2001, 2, 318-323.	4.5	132
11	Lipoprotein processing is required for virulence of Mycobacterium tuberculosisâ€. Molecular Microbiology, 2004, 52, 1543-1552.	2.5	132
12	Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nature Medicine, 1998, 4, 1343-1344.	30.7	128
13	Introducing mutations into a chromosomal rRNA gene using a genetically modified eubacterial host with a single rRNA operon. Molecular Microbiology, 1996, 22, 841-848.	2.5	101
14	Intrinsic rifamycin resistance of<i>Mycobacterium abscessus</i>is mediated by ADP-ribosyltransferase MAB_0591. Journal of Antimicrobial Chemotherapy, 2017, 72, 376-384.	3.0	101
15	Breaking down the wall: Fractionation of mycobacteria. Journal of Microbiological Methods, 2007, 68, 32-39.	1.6	98
16	Directed mutagenesis of <i>Mycobacterium smegmatis</i> 16S rRNA to reconstruct the <i>in vivo</i> evolution of aminoglycoside resistance in <i>Mycobacterium tuberculosis</i>. Molecular Microbiology, 2010, 77, 830-840.	2.5	97
17	The functions of OmpATb, a pore-forming protein of Mycobacterium tuberculosis. Molecular Microbiology, 2002, 46, 191-201.	2.5	96
18	Lipoprotein synthesis in mycobacteria. Microbiology (United Kingdom), 2007, 153, 652-658.	1.8	90

#	Article	IF	Citations
19	Dop functions as a depupylase in the prokaryotic ubiquitinâ€like modification pathway. EMBO Reports, 2010, 11, 791-797.	4.5	90
20	Antibodies protect against intracellular bacteria by Fc receptor-mediated lysosomal targeting. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20441-20446.	7.1	87
21	Engineering the rRNA decoding site of eukaryotic cytosolic ribosomes in bacteria. Nucleic Acids Research, 2007, 35, 6086-6093.	14.5	84
22	The role of ribosomal RNAs in macrolide resistance. Molecular Microbiology, 1997, 26, 469-480.	2.5	75
23	Lack of mismatch correction facilitates genome evolution in mycobacteria. Molecular Microbiology, 2004, 53, 1601-1609.	2.5	70
24	DNA damage induction of recA in Mycobacterium tuberculosis independently of RecA and LexA. Molecular Microbiology, 2002, 46, 791-800.	2.5	66
25	Deletion of <i>dop</i> in <i>Mycobacterium smegmatis</i> abolishes pupylation of protein substrates <i>in vivo</i>. Molecular Microbiology, 2010, 75, 744-754.	2.5	65
26	Identification of Apolipoprotein N-Acyltransferase (Lnt) in Mycobacteria. Journal of Biological Chemistry, 2009, 284, 27146-27156.	3.4	64
27	Binding of Neomycin-Class Aminoglycoside Antibiotics to Mutant Ribosomes with Alterations in the A Site of 16S rRNA. Antimicrobial Agents and Chemotherapy, 2006, 50, 1489-1496.	3.2	63
28	RecA-Mediated Gene Conversion and Aminoglycoside Resistance in Strains Heterozygous for rRNA. Antimicrobial Agents and Chemotherapy, 1999, 43, 447-453.	3.2	62
29	Instability and site-specific excision of integration-proficient mycobacteriophage L5 plasmids: development of stably maintained integrative vectors. International Journal of Medical Microbiology, 2001, 290, 669-675.	3.6	62
30	Whole-Genome Sequencing for Drug Resistance Profile Prediction in <i>Mycobacterium tuberculosis</i>. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	59
31	Mycobacterium bovis BCG recADeletion Mutant Shows Increased Susceptibility to DNA-Damaging Agents but Wild-Type Survival in a Mouse Infection Model. Infection and Immunity, 2001, 69, 3562-3568.	2.2	57
32	Elucidation of Mycobacterium abscessus aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes. Journal of Antimicrobial Chemotherapy, 2017, 72, 2191-2200.	3.0	55
33	Contribution of the multidrug efflux pump LfrA to innate mycobacterial drug resistance. FEMS Microbiology Letters, 2000, 193, 19-23.	1.8	54
34	Relief from Zmp1-Mediated Arrest of Phagosome Maturation Is Associated with Facilitated Presentation and Enhanced Immunogenicity of Mycobacterial Antigens. Vaccine Journal, 2011, 18, 907-913.	3.1	54
35	<i>Mycobacterium tuberculosis</i> lipoproteins in virulence and immunity â€“ fighting with a doubleâ€edged sword. FEBS Letters, 2016, 590, 3800-3819.	2.8	47
36	Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis. Vaccine, 2015, 33, 1353-1359.	3.8	45

#	Article	IF	Citations
37	TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. Frontiers in Immunology, 2017, 8, 1203.	4.8	44
38	Molecular Mechanisms of Intrinsic Streptomycin Resistance in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	43
39	Dissecting the complete lipoprotein biogenesis pathway in <i>Streptomyces scabies</i>. Molecular Microbiology, 2011, 80, 1395-1412.	2.5	42
40	The biological and structural characterization of Mycobacterium tuberculosis UvrA provides novel insights into its mechanism of action. Nucleic Acids Research, 2011, 39, 7316-7328.	14.5	40
41	Investigation of mycobacterial recA function: protein introns in the RecA of pathogenic mycobacteria do not affect competency for homologous recombination. Molecular Microbiology, 1998, 29, 1203-1214.	2.5	39
42	Effect of Î²-lactamase production and Î²-lactam instability on MIC testing results for Mycobacterium abscessus. Journal of Antimicrobial Chemotherapy, 2017, 72, 3070-3078.	3.0	38
43	BATF3-dependent dendritic cells drive both effector and regulatory T-cell responses in bacterially infected tissues. PLoS Pathogens, 2019, 15, e1007866.	4.7	38
44	Mycobacterium tuberculosis EsxO (Rv2346c) promotes bacillary survival by inducing oxidative stress mediated genomic instability in macrophages. Tuberculosis, 2016, 96, 44-57.	1.9	37
45	Characterization of the Mycobacterial NER System Reveals Novel Functions of the<i>uvrD1</i>Helicase. Journal of Bacteriology, 2009, 191, 555-562.	2.2	34
46	Lipoproteins of slow-growing Mycobacteria carry three fatty acids and are N-acylated by Apolipoprotein N-Acyltransferase BCG_2070c. BMC Microbiology, 2013, 13, 223.	3.3	32
47	Tuberculosis vaccine strain Mycobacterium bovis BCG Russia is a natural recA mutant. BMC Microbiology, 2008, 8, 120.	3.3	31
48	Crystal Structure of Mycobacterium tuberculosis Zinc-dependent Metalloprotease-1 (Zmp1), a Metalloprotease Involved in Pathogenicity. Journal of Biological Chemistry, 2011, 286, 32475-32482.	3.4	31
49	Mycobacteria: Genetics of Resistance and Implications for Treatment. Chemotherapy, 1999, 45, 95-108.	1.6	30
50	Functional Analyses of Mycobacterial Lipoprotein Diacylglyceryl Transferase and Comparative Secretome Analysis of a Mycobacterial <i>lgt</i> Mutant. Journal of Bacteriology, 2012, 194, 3938-3949.	2.2	30
51	LspA inactivation in Mycobacterium tuberculosis results in attenuation without affecting phagosome maturation arrest. Microbiology (United Kingdom), 2008, 154, 2991-3001.	1.8	28
52	Functional characterization of the <i>Mycobacterium tuberculosis</i> zinc metallopeptidase Zmp1 and identification of potential substrates. Biological Chemistry, 2012, 393, 631-640.	2.5	24
53	Lipoprotein Glycosylation by Protein-O-Mannosyltransferase (MAB_1122c) Contributes to Low Cell Envelope Permeability and Antibiotic Resistance of Mycobacterium abscessus. Frontiers in Microbiology, 2017, 8, 2123.	3.5	24
54	Discovery of the first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2508-2511.	2.2	22

#	Article	IF	Citations
55	Ribosomal drug resistance in mycobacteria. Research in Microbiology, 1996, 147, 59-67.	2.1	21
56	Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis. Vaccine, 2013, 31, 1057-1064.	3.8	19
57	Mortality from drug-resistant tuberculosis in high-burden countries comparing routine drug susceptibility testing with whole-genome sequencing: a multicentre cohort study. Lancet Microbe, The, 2021, 2, e320-e330.	7.3	19
58	Identification of novel scaffolds targeting Mycobacterium tuberculosis. Journal of Molecular Medicine, 2019, 97, 1601-1613.	3.9	18
59	A Mycobacterial smc Null Mutant Is Proficient in DNA Repair and Long-Term Survival. Journal of Bacteriology, 2008, 190, 452-456.	2.2	17
60	Phenylethyl Butyrate Enhances the Potency of Second-Line Drugs against Clinical Isolates of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 1142-1145.	3.2	17
61	BCG Î”zmp1 vaccine induces enhanced antigen specific immune responses in cattle. Vaccine, 2014, 32, 779-784.	3.8	17
62	A uniform cloning platform for mycobacterial genetics and protein production. Scientific Reports, 2018, 8, 9539.	3.3	17
63	Increased drug permeability of a stiffened mycobacterial outer membrane in cells lacking MFS transporter Rv1410 and lipoprotein LprG. Molecular Microbiology, 2019, 111, 1263-1282.	2.5	17
64	Cloning, expression and characterization of Mycobacterium tuberculosis lipoprotein LprF. Biochemical and Biophysical Research Communications, 2010, 391, 679-684.	2.1	16
65	Rifabutin Is Inactivated by Mycobacterium abscessus Arr. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	16
66	Inteins in mycobacterial GyrA are a taxonomic character. Microbiology (United Kingdom), 1998, 144, 589-591.	1.8	15
67	Chloroquine enhances the antimycobacterial activity of isoniazid and pyrazinamide by reversing inflammation-induced macrophage efflux. International Journal of Antimicrobial Agents, 2017, 50, 55-62.	2.5	15
68	Interaction of Rv1625c, a mycobacterial class IIIa adenylyl cyclase, with a mammalian congener. Molecular Microbiology, 2005, 57, 667-677.	2.5	14
69	Gene Replacement in Mycobacterium tuberculosis and Mycobacterium bovis BCG Using rpsL⁺ as a Dominant Negative Selectable Marker. , 2001, 54, 093-104.		13
70	Characterization of a Mycobacterium tuberculosis mutant deficient in pH-sensing adenylate cyclase Rv1264. International Journal of Medical Microbiology, 2006, 296, 563-566.	3.6	13
71	Semisynthetic Analogs of the Antibiotic Fidaxomicinâ€”Design, Synthesis, and Biological Evaluation. ACS Medicinal Chemistry Letters, 2020, 11, 2414-2420.	2.8	12
72	Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	12

#	Article	IF	Citations
73	Aquimarins, Peptide Antibiotics with Aminoâ€Modified Câ€Termini from a Spongeâ€Derived<i>Aquimarina</i>sp. Bacterium. Angewandte Chemie - International Edition, 2022, 61, .	13.8	12
74	A recA deletion mutant of Mycobacterium bovis BCG confers protection equivalent to that of wild-type BCG but shows increased genetic stability. Vaccine, 2003, 21, 4124-4127.	3.8	10
75	Synthesis and Biological Evaluation of Iodinated Fidaxomicin Antibiotics. Helvetica Chimica Acta, 2020, 103, e2000130.	1.6	10
76	In Vivo Splicing and Functional Characterization ofMycobacterium leprae RecA. Journal of Bacteriology, 2000, 182, 3590-3592.	2.2	9
77	Involvement of CD252 (CD134L) and IL-2 in the Expression of Cytotoxic Proteins in Bacterial- or Viral-Activated Human T Cells. Journal of Immunology, 2009, 182, 7569-7579.	0.8	9
78	Polyphosphates from <i>Mycobacteriumâ€ƒbovis</i>â€" potent inhibitors of classâ€ƒIII adenylate cyclases. FEBS Journal, 2009, 276, 1094-1103.	4.7	8
79	Drug Susceptibility Distributions of Mycobacterium chimaera and Other Nontuberculous Mycobacteria. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	8
80	Novel fidaxomicin antibiotics through site-selective catalysis. Communications Chemistry, 2021, 4, .	4.5	7
81	Mycobacterium tuberculosis Phosphoribosyltransferase Promotes Bacterial Survival in Macrophages by Inducing Histone Hypermethylation in Autophagy-Related Genes. Frontiers in Cellular and Infection Microbiology, 2021, 11, 676456.	3.9	7
82	Apramycin Overcomes the Inherent Lack of Antimicrobial Bactericidal Activity in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0151021.	3.2	7
83	KatG as Counterselection Marker for Nontuberculous Mycobacteria. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	6
84	<i>In Vitro</i> Bedaquiline and Clofazimine Susceptibility Testing in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2022, 66, e0234621.	3.2	6
85	Gene Replacement in Mycobacterium smegmatis Using a Dominant Negative Selectable Marker. , 1998, 101, 207-216.		4
86	Lipase Processing of Complex Lipid Antigens. Cell Chemical Biology, 2016, 23, 1044-1046.	5.2	4
87	A Î²-Lactamase Based Reporter System for ESX Dependent Protein Translocation in Mycobacteria. PLoS ONE, 2012, 7, e35453.	2.5	3
88	Photochemically-Mediated Inflammation and Cross-Presentation of Mycobacterium bovis BCG Proteins Stimulates Strong CD4 and CD8 T-Cell Responses in Mice. Frontiers in Immunology, 2022, 13, 815609.	4.8	3
89	Aquimarins, Peptide Antibiotics with Aminoâ€Modified Câ€Termini from a Spongeâ€Derived <i>Aquimarina</i> sp. Bacterium. Angewandte Chemie, 2022, 134, .	2.0	3
90	Tuberculosis vaccine strain Mycobacterium bovis BCG Russia is a natural recA mutant. Nature Precedings, 2008, , .	0.1	0